Compound Contains Two Or More C(=o)o Groups Patents (Class 514/547)
  • Patent number: 10668013
    Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 2, 2020
    Assignee: VITUX GROUP AS
    Inventors: Tore Seternes, Kurt Ingar Draget, Ingvild Johanne Haug
  • Patent number: 10660958
    Abstract: An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: May 26, 2020
    Assignee: TDELTAS LIMITED
    Inventor: Kieran Clarke
  • Patent number: 10646462
    Abstract: Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 12, 2020
    Assignee: University of South Florida
    Inventors: Dominic Paul D'Agostino, Patrick Arnold, Shannon Kesl
  • Patent number: 10640451
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 5, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10596141
    Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: March 24, 2020
    Assignee: Enzychem Lifesciences Corporation
    Inventors: Ki-Young Sohn, Jae Wha Kim
  • Patent number: 10588886
    Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 17, 2020
    Assignee: Enzychem Lifesciences Corporation
    Inventors: Ki-Young Sohn, Jae Wha Kim
  • Patent number: 10525028
    Abstract: [Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 7, 2020
    Assignee: NIPPON SUISAN KAISHA, LTD.
    Inventors: Jiro Takeo, Hiroyuki Kawahara
  • Patent number: 10501401
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: December 10, 2019
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10434340
    Abstract: A method of treating skin is disclosed. The method can include topically applying to skin in need thereof, an emulsion comprising palmitoyl tetrapeptide 7, water, glycerin, cetyl alcohol, denatured alcohol, stearic acid, dimethicone, squalane, mineral oil, and beeswax.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 8, 2019
    Assignee: Mary Kay Inc.
    Inventors: Dawn Burke-Colvin, Michelle Hines, David Gan
  • Patent number: 10434148
    Abstract: The present invention discloses a preparation method of an albumin peptide combination and the action of inhibiting the proliferation of cancer cells thereof, the preparation steps comprise: mixing albumin and water in proportion, heating, adjusting pH, adding alkaline protease to perform enzymatic hydrolysis, deactivating, filtrating; mixing Coix seed and water in proportion, decocting to extract, filtrating, adding certain proportional of water to filter residue, continue decocting to extract, collecting filtrates, determining solid matter content respectively, mixing two solutions, concentrating, spray drying, and obtaining an albumin peptide combination having the action of inhibiting the proliferation of cancer cells. The present invention found that, as compared with using Coix seed individually, the effect of inhibiting the proliferation of cancer cells of albumin peptide combination is stronger, and process is simpler.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: October 8, 2019
    Assignees: Nascent Peptide Biotechnology Limited
    Inventors: Dongliang Chen, Yang Zhang, Cong Zhou
  • Patent number: 10414713
    Abstract: The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 17, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Jia Li, Jingya Li, Mei Zhang, Zhifu Xie, Jingtao Wang, Dongdong Guo
  • Patent number: 10383894
    Abstract: A medicinal drug is administered to a person for treating allergic rhinitis, hemorrhoids, toothache, bromhidrosis, or urticaria. The medicinal drug is formed at least partially with salt of peroxymonosulfuric acid, preferably potassium hydrogen peroxymonosulfate.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: August 20, 2019
    Assignee: LuTran Industries, Inc.
    Inventors: David Van Tran, David Nguyen Tran
  • Patent number: 10329579
    Abstract: The present invention pertains to methods, means and uses of nucleic acids and polypeptides for conferring, modifying or improving plant resistance against fungal infections. Particularly, the invention provides nucleic acids and polypeptides for conferring, modifying or improving plant resistance against fungal infections. The invention also provides vectors, cells and plants. Also, the invention provides methods for creating corresponding plant cells and plants, and for identification of agents for conferring, modifying or improving plant resistance against fungal infections.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: June 25, 2019
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Holger Schultheiss, Nadine Tresch, Uwe Conrath, Katharina Goellner, Caspar Langenbach
  • Patent number: 10328046
    Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 25, 2019
    Assignee: DS Biopharma Limited
    Inventors: Adam Kelliher, Angus Morrison, Phil Knowles
  • Patent number: 10272056
    Abstract: The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; and administering an amount of a butyrate compound to the subject based at least partially on the determining step so as to promote Adenosine triphosphate (ATP) production in the subject as well as to methods of screening for compounds that restore cellular mitochondrial activity.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 30, 2019
    Assignee: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation
    Inventors: Anne Chiaramello, Martine Uittenbogaard
  • Patent number: 10258593
    Abstract: A semiochemical composition including methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is described. Methods to reduce social conflicts in multi-cat households or in catteries or kennels boarding cats are also disclosed, as well as methods for inducing social facilitation in cats.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 16, 2019
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Patent number: 10259772
    Abstract: An object of the present invention is to find a novel substance that is capable of efficiently promoting the proliferation of stem cells while maintaining the undifferentiated state thereof and to provide the substance as an agent for maintaining the undifferentiated state of stem cells or an agent for promoting the proliferation of stem cells. Another object of the present invention is to provide an agent for treating a wound that has a wound healing effect on the skin and is readily available in the field of skin regenerative medicine or cosmetic treatment, and safe and inexpensive.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 16, 2019
    Assignee: Nippon Menard Cosmetic Co., Ltd.
    Inventors: Seiji Hasegawa, Yu Inoue, Yuichi Hasebe, Tsutomu Sakaida
  • Patent number: 10227434
    Abstract: The invention relates to a composition for use in a Monosil process for the crosslinking of thermoplastic polyolefins which comprises (i) from 5 to 60% by weight content of caprylic acid (H3C(CH2)6COOH), (ii) content of at least one monounsaturated organofunctional alkoxysilane of the general formula I A-SiR2x(OR1)3-x??(I), where R1 is mutually independently a linear or branched hydrocarbon moiety having from 1 to 4 C atoms, R2 is methyl and x is 0 or 1 and A is a monovalent olefin group of the formula (R3)2C?C(R3)-Mk-, where k is 0 or 1, in which groups R3 are identical or different and R3 is a hydrogen atom or a methyl group and the group M is a group from this list: —CH2—, —(CH2)2—, —(CH2)3— and C(O)O—(CH2)3—, (iii) content of at least one free-radical generator and (iv) optionally content of at least one other component, where the entirety of all components (i) to (iv) gives 100% by weight.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 12, 2019
    Assignee: Evonik Degussa GmbH
    Inventors: Aristidis Ioannidis, Ioana-Elena Mihailescu, Bastian Bielawski, Kerstin Weissenbach
  • Patent number: 10166209
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: January 1, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Patent number: 10130672
    Abstract: The present invention relates to a composition of phenolic antioxidants obtained from oil palm, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) related infections. Accordingly, the composition having the said oil palm compounds can effectively inhibit various viruses, further supporting oil palm compounds as one of the broad spectrum antiviral drugs.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: November 20, 2018
    Assignee: Malaysian Palm Oil Board
    Inventors: Ravigadevi Sambanthamurthi, Kalyana Sundram P. Manickam, Yew Ai Tan, Mohd Basri bin Wahid
  • Patent number: 10123960
    Abstract: A double conjugate molecule made of a retinoid, an organic acid, particularly an a-hydroxy acid, and an alcohol or acyl group, is provided which is useful in treating skin conditions, particularly aging. The retinoid, organic acid, and alcohol/acyl group are preferably linked via ester bonds.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: November 13, 2018
    Assignee: PCR TECHNOLOGY HOLDINGS, LC
    Inventor: Joseph A. Lewis, II
  • Patent number: 10123554
    Abstract: The present invention pertains to a method for manufacturing a feed product comprising the steps of: providing a lactylate product, wherein the lactylate product comprises at least 30 wt, % of C10-C16-fatty acid lactylates, in liquid form at a first location; transferring lactylate product in the liquid form to a transport unit; transporting the lactylate product in the transport unit to a second location, with the lactylate product being in solid form, in liquid form, or in an intermediate state during transport; if the lactylate product is solidified or partly solidified, converting the lactylate product to the liquid form in the transport unit; removing the lactylate product from the transport unit in liquid form at the second location; and, contacting the lactylate product in liquid form with a feed product.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: November 13, 2018
    Assignee: PURAC BIOCHEM B.V.
    Inventors: Nikolaos Vogiatzis, Symone Kok, Barbara Lara Veldhuis-Stribos
  • Patent number: 10111848
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 30, 2018
    Assignees: National Institute of Health and Medical Research, Baylor Research Institute
    Inventors: Fanny Mochel, Raphael Schiffmann
  • Patent number: 10098964
    Abstract: The invention provides novel formulations comprising a stable inclusion complex of tributyrin and a cyclodextrin. In one particular embodiment, the formulation comprises an oven dried inclusion complex of tributyrin and ?-cyclodextrin that is effective in minimizing or preventing the unpleasant taste and odor of tributyrin, thus making it suitable for oral administration and delivery to the digestive tract and intestines. The invention provides compositions of these inclusion complexes and methods of using them that are advantageous as food, medicinal and other products, where the negative sensory properties of tributyrin can be a liability.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: October 16, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Joseph D. Donovan, Soo-Yeun Lee, Youngsoo Lee
  • Patent number: 10058527
    Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: August 28, 2018
    Assignees: ENZYCHEM LIFESCIENCES CORPORATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jae Wha Kim, Sei Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki-Young Sohn
  • Patent number: 10028928
    Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 24, 2018
    Assignee: Pronova Biopharma Norge AS
    Inventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Anette Mullertz
  • Patent number: 10022346
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 17, 2018
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Patent number: 9969681
    Abstract: The present invention relates to trisodium diethylenetriamine pentaacetic acid (DTPA) prodrugs, such as, for example, DTPA di-ethyl esters. The invention further relates to compositions comprising DTPA prodrugs and methods of using the same.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 15, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Michael Jay, Russell Mumper, James Huckle, Matthew Sadgrove
  • Patent number: 9938223
    Abstract: Disclosed are methods for the catalytic transesterification of compounds having one or more ester groups and groups reactive under transesterification conditions, such as 1,1-disubstituted alkene compounds, with alcohols or esters and novel compositions prepared therefrom. Further disclosed are novel compounds and compositions prepared as a result of the methods.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 10, 2018
    Assignee: Sirrus, Inc.
    Inventors: Jeffrey M. Sullivan, Aniruddha Palsule, Peter Rulon Stevenson, Kshitij Kishen Parab
  • Patent number: 9895337
    Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 20, 2018
    Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of Bioscience and Biotechnology
    Inventors: Jae Wha Kim, Sei Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Beom Su Park, Tae Suk Lee, Jong Koo Kang, Young Sik Jung, Ki-Young Sohn
  • Patent number: 9889106
    Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: February 13, 2018
    Assignee: DS BIOPHARMA LIMITED
    Inventors: Adam Kelliher, Angus Morrison, Phil Knowles
  • Patent number: 9833642
    Abstract: Disclosed is a method of firming skin or reducing the appearance of fine lines or wrinkles comprising topically applying, to skin in need thereof, a composition comprising palmitoyl tetrapeptide 7 and a dermatologically acceptable vehicle comprising water, glycerin, butylene glycol, propylene glycol, and a chelating agent, wherein topical application of the composition to the skin firms the skin or reduces the appearance of fine lines or wrinkles, and wherein the composition is not a sunless tanning composition.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: December 5, 2017
    Assignee: Mary Kay Inc.
    Inventors: Dawn Burke-Colvin, Michelle Hines, David Gan
  • Patent number: 9833007
    Abstract: An object of the present invention is to provide: a soy milk having a pleasant flavor and suppressed soybean odor, raw smell, astringency, and so forth; and a method for producing the soy milk. Specifically, provided are: the soy milk; a soy-milk flavor improver containing, as an active ingredient, a triacylglycerol having a medium-chain fatty acid with 6 to 12 carbon atoms as a constituent fatty acid; an improved soy milk containing a soy milk and the soy-milk flavor improver; and a food and a drink containing the improved soy milk. A method for producing the improved soy milk is also provided.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: December 5, 2017
    Assignee: THE NISSHIN OILLIO GROUP, LTD.
    Inventors: Tetsuo Takagi, Susumu Hikichi
  • Patent number: 9833430
    Abstract: This invention relates to compositions and methods for the therapy and diagnosis of neurodegenerative or neuromuscular disorders. More particularly, this invention relates to use of anaplerotic agents for treating, preventing, or delaying the onset of a neurodegenerative or neuromuscular disorder.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: December 5, 2017
    Assignee: The University of Queensland
    Inventors: Karin Borges, Shyuan T. Ngo
  • Patent number: 9808462
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 7, 2017
    Assignee: Tangent Reprofiling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Patent number: 9808438
    Abstract: The invention provides a pharmaceutical composition for preventing or treating mucositis, for example oral mucositis (e.g., oral ulceration) and gastrointestinal mucositis, comprising a monoacetyldiacylglycerol compound, especially PLAG, and a method of preventing or treating mucositis using the same.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: November 7, 2017
    Assignee: Enzychem Lifesciences Corporation
    Inventor: Ki-Young Sohn
  • Patent number: 9744192
    Abstract: The present invention provides methods of treating chronic rhinosinusitis that comprise administering a formulation of boric acid to the nasal and paranasal cavities of a patient in need. The present invention also provides for the use of a formulation comprising boric acid for the treatment of chronic rhinosinusitis.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: August 29, 2017
    Inventor: Lee A. Flippin
  • Patent number: 9744205
    Abstract: The present invention provides a method for treating breast cancer in a subject, which comprises administering to said subject an effective amount of an alcohol extract of dehulled adlay seeds. Preferably, an ethyl acetate sub-fraction of the alcohol extract of dehulled adlay seeds has a better effect in treating breast cancer.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: August 29, 2017
    Assignee: JOBEN BIO-MEDICAL CO., LTD.
    Inventors: Wenchang Chiang, Yueh-Hsiung Kuo, Yun-Lian Lin, Cheng-Pei Chung
  • Patent number: 9717756
    Abstract: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 1, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, William F. McKay, Jeffrey C. Marx
  • Patent number: 9656944
    Abstract: A novel fatty acid ester having the general formula R1—COOR2 wherein R1 and R2 are hydrocarbon groups derived from a branched fatty acid and an alcohol, respectively. R1 is derived from a branched fatty acid which has been refined from a commercially available acid to give a product with a high concentration of monobranched fatty acids and a low concentration of polybranched fatty acids. The use of the ester derived from the refined fatty acid is found to be particularly useful in personal care compositions, for example as an emollient.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: May 23, 2017
    Assignee: CRODA INTERNATIONAL PLC
    Inventors: Rebecca Louise Peevers, John Robin Latus, Jonathan David Townend
  • Patent number: 9585890
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 7, 2017
    Assignee: Tangent Reprofiling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Patent number: 9556138
    Abstract: The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; or pharmaceutically acceptable salts, polymorphs and derivatives thereof, and at least one pharmaceutically acceptable excipient. The present disclosure also relates to its application for preventing/curing/treating various acne conditions.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: January 31, 2017
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Somesh Sharma, Ashish Suthar, Kavita Salkar, Sandip Kedar
  • Patent number: 9557334
    Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: January 31, 2017
    Assignee: Run Them Sweet LLC
    Inventors: Michael A Horning, George A Brooks
  • Patent number: 9539225
    Abstract: A method for ameliorating and/or preventing cancerous anemia includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 10, 2017
    Assignee: SBI Pharmaceuticals Co., Ltd.
    Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata, Kiwamu Takahashi
  • Patent number: 9532963
    Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: January 3, 2017
    Assignee: Pronova Biopharma Norge AS
    Inventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Anette Müllertz
  • Patent number: 9475755
    Abstract: A method for ameliorating and/or preventing chronic kidney disease includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof as an active ingredient. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters, such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: October 25, 2016
    Assignee: SBI Pharmaceuticals Co., Ltd
    Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata, Takeo Kohda
  • Patent number: 9468229
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: October 18, 2016
    Assignees: NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH, BAYLOR RESEARCH INSTITUTE
    Inventors: Fanny Mochel, Raphael Schiffmann
  • Patent number: 9469598
    Abstract: A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: October 18, 2016
    Assignees: SBI Pharmaceuticals Co., Ltd., Tohoku University
    Inventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Takaaki Abe
  • Patent number: 9457087
    Abstract: The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: October 4, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Platscher, Alfred Hedinger
  • Patent number: 9439885
    Abstract: The present invention is directed to a method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with at least one diglyceride antimicrobial agent.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: September 13, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventor: Bryon W. Petschow